{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Garciaz S"],"funding":["NHMRC Project Grant","VCA Mid-Career Research Fellowship","Cancer Research UK","ARC Discovery Project Grant","European Union's Horizon 2020 research and innovation programme","NHMRC","NHMRC Investigator Grant","Susan G. Komen Career Catalyst Research Grant","Howard Hughes Medical Institute international research scholarship"],"pagination":["774-791"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9390741"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(3)"],"pubmed_abstract":["Cancer cell metabolism is increasingly recognized as providing an exciting therapeutic opportunity. However, a drug that directly couples targeting of a metabolic dependency with the induction of cell death in cancer cells has largely remained elusive. Here we report that the drug-like small-molecule ironomycin reduces the mitochondrial iron load, resulting in the potent disruption of mitochondrial metabolism. Ironomycin promotes the recruitment and activation of BAX/BAK, but the resulting mitochondrial outer membrane permeabilization (MOMP) does not lead to potent activation of the apoptotic caspases, nor is the ensuing cell death prevented by inhibiting the previously established pathways of programmed cell death. Consistent with the fact that ironomycin and BH3 mimetics induce MOMP thro"],"journal":["Cancer discovery"],"pubmed_title":["Pharmacologic Reduction of Mitochondrial Iron Triggers a Noncanonical BAX/BAK-Dependent Cell Death."],"pmcid":["PMC9390741"],"funding_grant_id":["GNT1176732","647973","#55008729","#1196755","20097","#1196749","GNT1146642","MCRF17020","DP200102693","CCR18548354"],"pubmed_authors":["Litalien V","Pomilio G","Kuzich JA","Muller S","Guirguis AA","MacPherson L","Chan KL","Dawson MA","Dawson SJ","Duprez E","Caneque T","Burr ML","Brown KK","Poplineau M","Wei AH","Rowe CL","Lam EYN","Rodriguez R","McArthur K","Motazedian A","Ramm G","Smith L","Liddicoat B","Garciaz S","Huang DCS","Brown FC","Chan YC","Tran K","Cox AG"],"additional_accession":[]},"is_claimable":false,"name":"Pharmacologic Reduction of Mitochondrial Iron Triggers a Noncanonical BAX/BAK-Dependent Cell Death.","description":"Cancer cell metabolism is increasingly recognized as providing an exciting therapeutic opportunity. However, a drug that directly couples targeting of a metabolic dependency with the induction of cell death in cancer cells has largely remained elusive. Here we report that the drug-like small-molecule ironomycin reduces the mitochondrial iron load, resulting in the potent disruption of mitochondrial metabolism. Ironomycin promotes the recruitment and activation of BAX/BAK, but the resulting mitochondrial outer membrane permeabilization (MOMP) does not lead to potent activation of the apoptotic caspases, nor is the ensuing cell death prevented by inhibiting the previously established pathways of programmed cell death. Consistent with the fact that ironomycin and BH3 mimetics induce MOMP thro","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2026-05-27T22:31:27.399Z","creation":"2025-02-19T02:37:55.262Z"},"accession":"S-EPMC9390741","cross_references":{"pubmed":["34862195"],"doi":["10.1158/2159-8290.CD-21-0522"]}}